Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Candida vaginitis: virulence, host response and vaccine prospects.

De Bernardis F, Graziani S, Tirelli F, Antonopoulou S.

Med Mycol. 2018 Apr 1;56(suppl_1):26-31. doi: 10.1093/mmy/myx139. Review.

PMID:
29538739
2.

Use of SCW4 gene primers in PCR methods for the identification of six medically important Aspergillus species.

Arancia S, Sandini S, De Carolis E, Vella A, Sanguinetti M, Norelli S, De Bernardis F.

New Microbiol. 2016 Oct;39(4):274-286. Epub 2016 Jul 25.

3.

Studies of Immune Responses in Candida vaginitis.

De Bernardis F, Arancia S, Sandini S, Graziani S, Norelli S.

Pathogens. 2015 Oct 9;4(4):697-707. doi: 10.3390/pathogens4040697. Review.

4.

Candida albicans OPI1 regulates filamentous growth and virulence in vaginal infections, but not inositol biosynthesis.

Chen YL, de Bernardis F, Yu SJ, Sandini S, Kauffman S, Tams RN, Bethea E, Reynolds TB.

PLoS One. 2015 Jan 20;10(1):e0116974. doi: 10.1371/journal.pone.0116974. eCollection 2015.

5.

Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis.

De Bernardis F, Arancia S, Tringali G, Greco MC, Ragazzoni E, Calugi C, Trabocchi A, Sandini S, Graziani S, Cauda R, Cassone A, Guarna A, Navarra P.

J Pharm Pharmacol. 2014 Aug;66(8):1094-101. doi: 10.1111/jphp.12240. Epub 2014 Mar 13.

PMID:
24628362
6.

AIDS-related mycoses: the way forward.

Brown GD, Meintjes G, Kolls JK, Gray C, Horsnell W; Working Group from the EMBO-AIDS Related Mycoses Workshop, Achan B, Alber G, Aloisi M, Armstrong-James D, Beale M, Bicanic T, Black J, Bohjanen P, Botes A, Boulware DR, Brown G, Bunjun R, Carr W, Casadevall A, Chang C, Chivero E, Corcoran C, Cross A, Dawood H, Day J, De Bernardis F, De Jager V, De Repentigny L, Denning D, Eschke M, Finkelman M, Govender N, Gow N, Graham L, Gryschek R, Hammond-Aryee K, Harrison T, Heard N, Hill M, Hoving JC, Janoff E, Jarvis J, Kayuni S, King K, Kolls J, Kullberg BJ, Lalloo DG, Letang E, Levitz S, Limper A, Longley N, Machiridza TR, Mahabeer Y, Martinsons N, Meiring S, Meya D, Miller R, Molloy S, Morris L, Mukaremera L, Musubire AK, Muzoora C, Nair A, Nakiwala Kimbowa J, Netea M, Nielsen K, O'hern J, Okurut S, Parker A, Patterson T, Pennap G, Perfect J, Prinsloo C, Rhein J, Rolfes MA, Samuel C, Schutz C, Scriven J, Sebolai OM, Sojane K, Sriruttan C, Stead D, Steyn A, Thawer NK, Thienemann F, Von Hohenberg M, Vreulink JM, Wessels J, Wood K, Yang YL.

Trends Microbiol. 2014 Mar;22(3):107-9. doi: 10.1016/j.tim.2013.12.008.

7.

IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis.

De Luca A, Carvalho A, Cunha C, Iannitti RG, Pitzurra L, Giovannini G, Mencacci A, Bartolommei L, Moretti S, Massi-Benedetti C, Fuchs D, De Bernardis F, Puccetti P, Romani L.

PLoS Pathog. 2013;9(7):e1003486. doi: 10.1371/journal.ppat.1003486. Epub 2013 Jul 11.

8.

Comparison of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis adhesive properties and pathogenicity.

Bertini A, De Bernardis F, Hensgens LA, Sandini S, Senesi S, Tavanti A.

Int J Med Microbiol. 2013 Mar;303(2):98-103. doi: 10.1016/j.ijmm.2012.12.006. Epub 2013 Feb 9.

PMID:
23403338
9.

Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype.

Calugi C, Trabocchi A, De Bernardis F, Arancia S, Navarra P, Cauda R, Cassone A, Guarna A.

Bioorg Med Chem. 2012 Dec 15;20(24):7206-13. doi: 10.1016/j.bmc.2012.09.031. Epub 2012 Oct 17.

PMID:
23123016
10.

Near-infrared background anisotropies from diffuse intrahalo light of galaxies.

Cooray A, Smidt J, De Bernardis F, Gong Y, Stern D, Ashby ML, Eisenhardt PR, Frazer CC, Gonzalez AH, Kochanek CS, Kozłowski S, Wright EL.

Nature. 2012 Oct 25;490(7421):514-6. doi: 10.1038/nature11474.

PMID:
23099405
11.

A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models.

De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, Moser C, Cassone A.

Vaccine. 2012 Jun 22;30(30):4490-8. doi: 10.1016/j.vaccine.2012.04.069. Epub 2012 May 3.

PMID:
22561143
12.

Peptides of the constant region of antibodies display fungicidal activity.

Polonelli L, Ciociola T, Magliani W, Zanello PP, D'Adda T, Galati S, De Bernardis F, Arancia S, Gabrielli E, Pericolini E, Vecchiarelli A, Arruda DC, Pinto MR, Travassos LR, Pertinhez TA, Spisni A, Conti S.

PLoS One. 2012;7(3):e34105. doi: 10.1371/journal.pone.0034105. Epub 2012 Mar 21.

13.

The MP65 gene is required for cell wall integrity, adherence to epithelial cells and biofilm formation in Candida albicans.

Sandini S, Stringaro A, Arancia S, Colone M, Mondello F, Murtas S, Girolamo A, Mastrangelo N, De Bernardis F.

BMC Microbiol. 2011 May 16;11:106. doi: 10.1186/1471-2180-11-106.

14.

A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine.

Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, De Bernardis F.

FEMS Immunol Med Microbiol. 2011 Jul;62(2):215-24. doi: 10.1111/j.1574-695X.2011.00802.x. Epub 2011 Apr 28.

15.

Rapid, simple, and low-cost identification of Candida species using high-resolution melting analysis.

Arancia S, Sandini S, De Bernardis F, Fortini D.

Diagn Microbiol Infect Dis. 2011 Mar;69(3):283-5. doi: 10.1016/j.diagmicrobio.2010.10.003.

PMID:
21353953
16.

Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice.

Ferrari S, Sanguinetti M, De Bernardis F, Torelli R, Posteraro B, Vandeputte P, Sanglard D.

Antimicrob Agents Chemother. 2011 May;55(5):1852-60. doi: 10.1128/AAC.01271-10. Epub 2011 Feb 14.

17.

Plant production of anti-β-glucan antibodies for immunotherapy of fungal infections in humans.

Capodicasa C, Chiani P, Bromuro C, De Bernardis F, Catellani M, Palma AS, Liu Y, Feizi T, Cassone A, Benvenuto E, Torosantucci A.

Plant Biotechnol J. 2011 Sep;9(7):776-87. doi: 10.1111/j.1467-7652.2010.00586.x. Epub 2011 Jan 25.

18.

Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes.

De Bernardis F, Santoni G, Boccanera M, Lucciarini R, Arancia S, Sandini S, Amantini C, Cassone A.

FEMS Yeast Res. 2010 Jun;10(4):432-40. doi: 10.1111/j.1567-1364.2010.00620.x. Epub 2010 Mar 8.

19.

Outcome of experimental rat vaginitis by Candida albicans isolates with different karyotypes.

Tavanti A, Campa D, Arancia S, Hensgens LA, de Bernardis F, Senesi S.

Microb Pathog. 2010 Jul-Aug;49(1-2):47-50. doi: 10.1016/j.micpath.2010.02.010. Epub 2010 Apr 9.

PMID:
20382215
20.

Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.

Trabocchi A, Mannino C, Machetti F, De Bernardis F, Arancia S, Cauda R, Cassone A, Guarna A.

J Med Chem. 2010 Mar 25;53(6):2502-9. doi: 10.1021/jm901734u.

PMID:
20184325
21.

Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence.

Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, Mignogna G, Maras B, Colone M, Stringaro A, Zamboni S, Feizi T, Cassone A.

PLoS One. 2009;4(4):e5392. doi: 10.1371/journal.pone.0005392. Epub 2009 Apr 28.

22.

Use of 65kDa mannoprotein gene primers in PCR methods for the identification of five medically important Candida species.

Arancia S, Sandini S, Cassone A, De Bernardis F.

Mol Cell Probes. 2009 Oct;23(5):218-26. doi: 10.1016/j.mcp.2009.04.003. Epub 2009 Apr 22.

PMID:
19393314
23.

Transcriptional profiling of the Candida albicans Ssk1p receiver domain point mutants and their virulence.

Menon V, De Bernardis F, Calderone R, Chauhan N.

FEMS Yeast Res. 2008 Aug;8(5):756-63. doi: 10.1111/j.1567-1364.2008.00404.x. Epub 2008 Jul 8.

24.

Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans.

Angiolella L, Stringaro AR, De Bernardis F, Posteraro B, Bonito M, Toccacieli L, Torosantucci A, Colone M, Sanguinetti M, Cassone A, Palamara AT.

Antimicrob Agents Chemother. 2008 Mar;52(3):927-36. doi: 10.1128/AAC.01223-07. Epub 2008 Jan 7.

25.

Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Cassone A, De Bernardis F, Santoni G.

Infect Immun. 2007 Oct;75(10):4675-86. Epub 2007 Jun 11. Review. No abstract available.

26.

The 65 kDa mannoprotein gene of Candida albicans encodes a putative beta-glucanase adhesin required for hyphal morphogenesis and experimental pathogenicity.

Sandini S, La Valle R, De Bernardis F, Macrì C, Cassone A.

Cell Microbiol. 2007 May;9(5):1223-38. Epub 2007 Jan 9.

PMID:
17217426
27.

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.

De Bernardis F, Liu H, O'Mahony R, La Valle R, Bartollino S, Sandini S, Grant S, Brewis N, Tomlinson I, Basset RC, Holton J, Roitt IM, Cassone A.

J Infect Dis. 2007 Jan 1;195(1):149-57. Epub 2006 Nov 20.

PMID:
17152019
29.

Azole resistance of Candida glabrata in a case of recurrent fungemia.

Posteraro B, Tumbarello M, La Sorda M, Spanu T, Trecarichi EM, De Bernardis F, Scoppettuolo G, Sanguinetti M, Fadda G.

J Clin Microbiol. 2006 Aug;44(8):3046-7.

30.

Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis.

De Bernardis F, Lucciarini R, Boccanera M, Amantini C, Arancia S, Morrone S, Mosca M, Cassone A, Santoni G.

Infect Immun. 2006 Jul;74(7):4282-94.

31.

Use of 65 kDa mannoprotein gene primers in Real Time PCR identification of Candida albicans in biological samples.

Arancia S, Carattoli A, La Valle R, Cassone A, De Bernardis F.

Mol Cell Probes. 2006 Oct;20(5):263-8. Epub 2006 Feb 23.

PMID:
16616453
32.

A novel glyco-conjugate vaccine against fungal pathogens.

Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A.

J Exp Med. 2005 Sep 5;202(5):597-606.

33.

An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis.

Cassone A, De Bernardis F, Torososantucci A.

Curr Mol Med. 2005 Jun;5(4):377-82. Review.

PMID:
15977993
34.

Construction and use of PCR primers from a 65 kDa mannoprotein gene for identification of C. albicans.

Arancia S, Sandini S, Cassone A, De Bernardis F, La Valle R.

Mol Cell Probes. 2004 Jun;18(3):171-5.

PMID:
15135451
35.
36.

Lack of circulating Candida mannoprotein antigen in patients with focal hepatosplenic candidiasis.

Girmenia C, Martino P, De Bernardis F, Boccanera M, Cassone A.

J Med Microbiol. 2004 Feb;53(Pt 2):103-6.

PMID:
14729929
37.

Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis.

Polonelli L, Magliani W, Conti S, Bracci L, Lozzi L, Neri P, Adriani D, De Bernardis F, Cassone A.

Infect Immun. 2003 Nov;71(11):6205-12.

38.

In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.

Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A.

J Antimicrob Chemother. 2003 May;51(5):1223-9. Epub 2003 Mar 28.

PMID:
12668571
39.

Detection of human P-glycoprotein-like molecule in azole-resistant Candida albicans from HIV+ patients.

Stringaro A, Molinari A, Calcabrini A, Arancia G, Ceddia PG, Cianfriglia M, Poloni F, Mondello F, Angiolella L, De Bernardis F, Cassone A.

Microb Drug Resist. 2002 Fall;8(3):235-44.

PMID:
12363014
40.

Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors.

Santoni G, Boccanera M, Adriani D, Lucciarini R, Amantini C, Morrone S, Cassone A, De Bernardis F.

Infect Immun. 2002 Sep;70(9):4791-7.

41.
42.

New immunotherapeutic strategies to control vaginal candidiasis.

Magliani W, Conti S, Cassone A, De Bernardis F, Polonelli L.

Trends Mol Med. 2002 Mar;8(3):121-6. Review.

PMID:
11879772
43.

Recombinant Streptococcus gordonii for mucosal delivery of a scFv microbicidal antibody.

Oggioni MR, Beninati C, Boccanera M, Medaglini D, Spinosa MR, Maggi T, Conti S, Magliani W, De Bernardis F, Teti G, Cassone A, Pozzi G, Polonelli L.

Int Rev Immunol. 2001;20(2):275-87. Review.

PMID:
11878770
44.

Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects.

Cassone A, Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Chiani P, Cauda R.

J Infect Dis. 2002 Jan 15;185(2):188-95. Epub 2002 Jan 3.

PMID:
11807692
45.
46.

Aspartyl proteinases of Candida albicans and their role in pathogenicity.

De Bernardis F, Sullivan PA, Cassone A.

Med Mycol. 2001 Aug;39(4):303-13. Review.

PMID:
11556759
47.

Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria.

Beninati C, Oggioni MR, Boccanera M, Spinosa MR, Maggi T, Conti S, Magliani W, De Bernardis F, Teti G, Cassone A, Pozzi G, Polonelli L.

Nat Biotechnol. 2000 Oct;18(10):1060-4.

PMID:
11017043
48.

Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans.

de Bernardis F, Santoni G, Boccanera M, Spreghini E, Adriani D, Morelli L, Cassone A.

Infect Immun. 2000 Jun;68(6):3297-304.

49.

Expression of the complement-binding protein (MP60) of Candida albicans in experimental vaginitis.

Stringaro A, Crateri P, Adriani D, Arancia G, Cassone A, Calderone RA, De Bernardis F.

Mycopathologia. 1998-1999;144(3):147-52.

PMID:
10531681
50.

Biotyping and virulence properties of skin isolates of Candida parapsilosis.

De Bernardis F, Mondello F, San Millàn R, Pontòn J, Cassone A.

J Clin Microbiol. 1999 Nov;37(11):3481-6.

Supplemental Content

Loading ...
Support Center